Ying Kai Chan

Ying Kai Chan

Company: Allyx Therapeutics

Job title: Chief Scientific Officer


Ying Kai Chan is Chief Scientific Officer at Ally Therapeutics, a venture-backed gene therapy company, and Visiting Scholar at Harvard Medical School. Previously, he served as junior faculty at Harvard University. He performed postdoctoral research at Harvard Medical School, where he also received a Ph.D. in Microbiology and Immunobiology and a certificate in Human Biology and Translational Medicine. His research interests are at the interface of viruses and the human immune system, with a focus on molecular engineering of desired viral and immune functions. He is currently exploring innovative technologies to modulate innate immune responses to AAV gene therapy.


Next Generation Design of Immune-Evading AAV Vectors 3:20 pm

• AAV vectors and the challenge of immune responses • Drivers of AAV immunogenicity • Design of AAV vectors that evade immune responsesRead more

day: Day Two

Live Q&A – Ask the speakers your questions 3:50 pm

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.